Address: 18 Kaihua Road,
Tianjin Huayan Hi Tech Industry ParkFukang Road,
Nankai district, Tianjin 300384,China
Tel: +86 22 83 71 03 43
Beaufour IPSEN entered China in 1992. In 1997, the group invested 200 million RMB to build Beaufour IPSEN (Tianjin) Pharmaceutical Co., Ltd., a Sino-French joint venture in Tianjin Huayuan Hi-Tech Industry Park where it occupies a surface area of 25 000 m2.
Beaufour IPSEN (Tianjin) Pharmaceutical Co., Ltd. now has almost 300 employees and there are 19 offices in China. In April 2000, Beaufour IPSEN (Tianjin) Pharmaceutical Co., Ltd. started the local production of smecta® – a mucous protective agent of digestive tract.
China is one of the most important markets for the development of Beaufour IPSEN group and Beaufour IPSEN is preparing to expend its dimension in China and it is expected to launch 2 or 3 products every year. The target of Beaufour IPSEN (Tianjin) Pharmaceutical Co., Ltd. is to be the leader in every one of its segments and to be one of the top 30 pharmaceutical enterprises of China.
Endocrinology, Oncology, Haemotology, Neurology
Your background before joining Beaufour Ipsen is quite unique among country managers of pharmaceutical companies: working many years in academia and focused very much on Asian studies. What brought you…
In recent years, global pharma’s Business Development (BD) operations in Asia have evolved from primarily managing global agreements locally to engaging in more complex tasks like contract negotiation and due…
Since it was established in 1988, PhIRDA, an organization that groups together China’s pharma innovators, research institutions and investors has played an active role in the evolution of China’s biopharma…
Han Yahui from Chinese folic acid specialist Scrianen outlines her company’s role in keeping mothers and newborns healthy in China, Scrianen’s approach to international partnerships, and the next horizons in…
In 2023, the first full year after the COVID-19 pandemic, the National Medical Products Administration (NMPA) set a new record by approving the highest number of new drugs in China…
Prof. Song Ruilin outlines the Chinese (bio)pharmaceutical industry’s progress across the three key pillars of innovation, industrialization, and internationalization in recent years. While a downturn in the global economy and…
Chinese biotech Jacobio has made remarkable strides in pioneering first-in-class drug research, with their SHP2 inhibitor project only the second globally to initiate a clinical trial for a novel target…
Amid geopolitical tensions and a drop in foreign investments, China continues to encourage international companies to increase their Chinese footprint. At this week’s China Development Forum (CDF), CEOs from Pfizer,…
The latest news from Chinese pharma, including progress on the US Senate bill targeting BGI and WuXi AppTec, a report on why drug research is slowing in the country, and…
No longer a fledgling biotech, oncology-focused BeiGene, originally created in China in 2010 with the idea of carrying out world-class research there, has since expanded its global reach and garnered…
The biggest pharma industry stories coming out of China, including the impact of the US Biosecure act on Chinese giants WuXi AppTec and WuXi Bio; Novartis’ acquisition of SanReno Therapeutics;…
Two leading regional pharma executives, from Eli Lilly and Boehringer Ingelheim respectively have recently moved to head up China operations; perhaps a sign that despite recent geopolitical tensions, multinational biopharma…
The latest pharma industry and healthcare news coming out of China including AstraZeneca’s acquisition of Gracell Biotechnologies; the alarming drop in enrolment in China’s state health insurance system; Huadong Medicine/Impact…
See our Cookie Privacy Policy Here
